Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo
Xianli Tong, Qun Wang, Dongde Wu, et al.
Biochemical and Biophysical Research Communications (2019) Vol. 523, Iss. 1, pp. 147-152
Closed Access | Times Cited: 18

Showing 18 citing articles:

Recent progress in treatment of hepatocellular carcinoma.
Zhiqian Chen, Hao Xie, Mingming Hu, et al.
PubMed (2020) Vol. 10, Iss. 9, pp. 2993-3036
Closed Access | Times Cited: 262
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 7
An update of new small-molecule anticancer drugs approved from 2015 to 2020
Xiaoxia Liang, Pan Wu, Qian Yang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 220, pp. 113473-113473
Closed Access | Times Cited: 41
RSK inhibitors as potential anticancer agents: Discovery, optimization, and challenges
Ying Sun, Lichao Tang, Chengyong Wu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 251, pp. 115229-115229
Closed Access | Times Cited: 12
Adenosine diphosphate stimulates VEGF-independent choroidal endothelial cell proliferation: A potential escape from anti-VEGF therapy
Nilima Biswas, Tommaso Mori, Naresh Kumar Ragava Chetty Nagaraj, et al.
Proceedings of the National Academy of Sciences (2025) Vol. 122, Iss. 4
Open Access
Discovery of 2,4-dianilinopyrimidine derivatives as novel p90 ribosomal S6 protein kinase (RSK) inhibitors
Chun Han, Guo Chaohua, Xumei Zheng, et al.
European Journal of Medicinal Chemistry (2025), pp. 117590-117590
Closed Access
Insights into Sorafenib resistance in hepatocellular carcinoma: Mechanisms and therapeutic aspects.
Eman H. Yousef, Amal M. El Gayar, Nada F. Abo El‐Magd
Critical Reviews in Oncology/Hematology (2025), pp. 104765-104765
Closed Access
Monocyte Chemoattractant Protein 1 Promotes VEGF-A Expression in OSCC by Activating ILK and MEK1/2 Signaling and Downregulating miR-29c
Ming‐Yu Lien, An‐Chen Chang, Hsiao‐Chi Tsai, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 25
LIF, a mitogen for choroidal endothelial cells, protects the choriocapillaris: implications for prevention of geographic atrophy
Pin Li, Qin Li, Nilima Biswas, et al.
EMBO Molecular Medicine (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 18
Blocking MAPK/ERK pathway sensitizes hepatocellular carcinoma cells to temozolomide via downregulating MGMT expression
Qiang Li, Bingjie Ren, Qi Gui, et al.
Annals of Translational Medicine (2020) Vol. 8, Iss. 20, pp. 1305-1305
Open Access | Times Cited: 19
Discovery of potential RSK1 inhibitors for cancer therapy using virtual screening, molecular docking, molecular dynamics simulation, and MM/GBSA calculations
Sevil Kalın, Ferah Cömert Önder
Journal of Biomolecular Structure and Dynamics (2023), pp. 1-21
Open Access | Times Cited: 7
Cobimetinib Sensitizes Cervical Cancer to Paclitaxel via Suppressing Paclitaxel-Induced ERK Activation
Yuan Liu, Runsheng Zhao, Xiaomin Qin, et al.
Pharmacology (2022) Vol. 107, Iss. 7-8, pp. 398-405
Closed Access | Times Cited: 9
Analysis of nitrogen metabolism-related gene expression in hepatocellular carcinoma to establish relevant indicators for prediction of prognosis and guidance of immunotherapy
Jianwen Duan, Renya Jiang, Hongbo Shen, et al.
Computer Methods in Biomechanics & Biomedical Engineering (2024), pp. 1-17
Closed Access | Times Cited: 1
Emerging drugs for the treatment of chronic myelomonocytic leukemia
Jorge Ramos Perez, Guillermo Montalban‐Bravo
Expert Opinion on Emerging Drugs (2020) Vol. 25, Iss. 4, pp. 515-529
Closed Access | Times Cited: 6
Deciphering essential druggable genes reveals potential immune-inflammatory axis in hepatocellular carcinoma
Xiaoren Wang, Xudong Cui, Wencan Wang, et al.
Computers in Biology and Medicine (2023) Vol. 167, pp. 107625-107625
Closed Access | Times Cited: 2
MEK inhibition by trametinib overcomes chemoresistance in preclinical nasopharyngeal carcinoma models
Xing Gong, Lei Fan, Pu Wang
Anti-Cancer Drugs (2021) Vol. 32, Iss. 9, pp. 978-985
Closed Access | Times Cited: 5
Protein kinase N1 promotes proliferation and invasion of liver cancer
Xia Wang, Yansong Ge, Mingqi Shi, et al.
Experimental and Therapeutic Medicine (2021) Vol. 21, Iss. 6
Open Access | Times Cited: 4
Preclinical Activity of Cobimetinib Alone or in Combination with Chemotherapy and Targeted Therapies in Renal Cell Carcinoma
Lichen Zhang, Deqiong Xie, Yonghua Lei, et al.
Future Oncology (2021) Vol. 17, Iss. 23, pp. 3051-3060
Closed Access | Times Cited: 3
Resistance to Antiangiogenic Therapy in Hepatocellular Carcinoma: From Molecular Mechanisms to Clinical Impact
Piera Federico, Emilio Francesco Giunta, Andrea Tufo, et al.
Cancers (2022) Vol. 14, Iss. 24, pp. 6245-6245
Open Access | Times Cited: 2
Page 1

Scroll to top